Ashley Chan

Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.

Findings presented at the Gastrointestinal Cancers Symposium showed the efficacy of Krazati and Erbitux for some patients with unresectable or metastatic colorectal cancer.

Treatment with five-fraction SBRT for prostate cancer may be more convenient than receiving traditional radiation therapy techniques, an expert said.

Utilizing tools such as spreadsheet trackers can make a big difference when organizing cancer-related medical bills and noting out-of-pocket maximums.

When insurance denies coverage of cancer treatment, patients with cancer don’t need to take no for an answer, an expert explained.

From a Pro Football Hall of Famer announcing his diagnosis to an R&B star’s latest update, here’s what’s happening in the cancer space this week.

Treatment with UGN-102 has shown promise as a non-surgical alternative when compared with a surgical approach for certain patients with bladder cancer.

A study showed that patients with prostate cancer should consider the long-term side effects of treatments before deciding on the appropriate options.

With a significant change happening in the Medicare space in early 2025, patients with cancer eligible for Medicare may see its benefits soon.

The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak or observation.

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell carcinoma.

From Gerry Turner announcing he has cancer to the return of a Chicago Cubs legend’s disease, here’s what’s happening in the cancer space this week.

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.

Patients with early breast cancer who are older may experience high-grade immune-related side effects after receiving immune checkpoint inhibitors.

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.

Treatment with five-fraction SBRT could be effective versus traditional radiation in certain patients with low- or intermediate-risk prostate cancer.

From a Hollywood star sharing an uplifting update to the death of a three-time boxing champion, here’s what’s happening in the cancer space this week.

Patients with locally advanced pancreatic cancer demonstrated a two-month difference in survival with tumor-treating fields versus chemotherapy.

In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.

Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than published data, an expert said.

In patients with low-grade prostate cancer, adhering to the recommended dietary guidelines may slow the risk of prostate cancer progression.

A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus endocrine therapy.

Patients with advanced Hodgkin lymphoma demonstrated significantly improved survival benefits with an Opdivo regimen versus an Adcetris regimen.

For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how treatments are given.

From the deaths of actor Paul Teal and Chicago Bulls player Bob Love to a contestant on “Jeopardy!” revealing his colon cancer diagnosis, here’s what’s happening in the oncology space this week.

Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated beneficial responses.

Patients with relapsed or refractory MDS may experience improved overall survival with DLI, depending on certain prognostic factors.

A trial evaluating the tamibarotene-Vidaza combination in certain patients with newly diagnosed high-risk MDS will be discontinued.

RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more research is necessary.

In patients with oropharyngeal cancer, deciding whether radiation therapy or surgery is the best option depends on their lifestyle and their values.